TeleFirst Med vs Embody
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
TeleFirst Med
Best for: coaching bundled into the price rather than sold separately
Visit TeleFirst Med →
Embody
Best for: knowing which pharmacy fills the vial — it names RedRock Pharmacy
Visit Embody →Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, Embody starts at $79/mo, and Embody finishes ahead, 9.3 to 3.9. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
TeleFirst Med
Pricing not publicly listed.
Embody
Checkout: '$79/mo flat forever' (strikethrough $299); bundles $76/$73/$69 per month on 3/6/12-mo. CAVEAT: T&C list price is $199/mo — the $79 depends on the auto-applied SUMMER promo marketed as permanently locked; Trustpilot complaints allege the lock was not always honored.
Checkout tile 'Flat rate at $119/month (strikethrough $349)'; homepage 'starting at $129/month'; bundles $126/$123/$119 per month.
New oral semaglutide $229/mo.
Oral tirzepatide $329/mo; gum bundles to $299/mo at 12-month.
What’s included
TeleFirst Med
Covered by the monthly price
Medication
Charged on top
Clinician visits
In the price
Shipping
Not stated
Lab work
Not stated
Coaching
In the price
Embody
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
TeleFirst Med
3.9/10
Embody
9.3/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | TeleFirst Med | Embody |
|---|---|---|
| Starting Price | — | $79/mo |
| Features | ✓8 features | 6 features |
| States Available | 2 | ✓50 |
| Compounded | — | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
About TeleFirst Med
The GLP-1 route at TeleFirst Med costs $120 for an evaluation, and that is the only figure published; the drug itself is billed separately by whichever pharmacy you already use. A licensed doctor decides whether you qualify, and what gets written is real brand-name medication, never compounded. No mail-order compounded program exists at all. Marketing promises no insurance hassle and no prior authorization. Coverage stops at Texas and North Carolina, from a small practice reporting 500+ patients, alongside its virtual urgent-care and primary-care work.
Read our full TeleFirst Med review →About Embody
Embody sells compounded semaglutide and tirzepatide by injection, plus a compounded oral tirzepatide gum that is unique in the category. Flat-rate pricing is aggressive, coverage runs to all 50 states, and clinician messaging is available 24/7 under a board-certified internal medicine CMO.
Read our full Embody review →Pros & Cons
TeleFirst Med
What we like
- The monthly figure covers consult and coaching
- No FDA warning letter matched this operator when we searched our enforcement register
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Watch-outs
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- Billed separately from the monthly figure: medication
- Coverage is published for 2 states only, so this may not reach you
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
Embody
What we like
- Semaglutide at $79 a month, 58% below the $189 median for the same drug and form across this register
- Tirzepatide at $129 a month, 52% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- Names 4 dispensing pharmacies, which most sellers in this register do not do
- No FDA warning letter matched this operator when we searched our enforcement register
- Both oral and injectable options are on record, so the format is a choice rather than a condition
Watch-outs
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Embody takes it, 9.3 against 3.9, and it is especially strong on knowing which pharmacy fills the vial — it names RedRock Pharmacy. TeleFirst Med is no weak second and may fit you better on coaching bundled into the price rather than sold separately.
Choose TeleFirst Med if…
You want coaching bundled into the price rather than sold separately.
Choose Embody if…
You want knowing which pharmacy fills the vial — it names RedRock Pharmacy and an opening price near $79 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Oak
Semaglutide at $119/month, 37% under the register median
From $119/mo
Get started →Found
Tirzepatide at $169/month, 37% under the register median
From $99/mo
Get started →Telos Rx
Starting below a standard dose, with microdose tiers
From $49/mo
Get started →TeleFirst Med vs Embody: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring TeleFirst Med and Embody head-to-heads in the same category.
- TeleFirst Med vs Trimi Health
- TeleFirst Med vs He & She MD
- TeleFirst Med vs Lean Meds
- Embody vs NextMeds
- Embody vs bmiMD
- Embody vs CoreAge Rx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.